Erasca Future Growth
Future criteria checks 0/6
Erasca's earnings are forecast to decline at 7% per annum while its annual revenue is expected to grow at 68.6% per year. EPS is expected to decline by 0.02% per annum. Return on equity is forecast to be -67.5% in 3 years.
Key information
-7.0%
Earnings growth rate
-0.02%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 68.6% |
Future return on equity | -67.5% |
Analyst coverage | Good |
Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -186 | -182 | N/A | 4 |
12/31/2025 | 1 | -168 | -159 | -152 | 6 |
12/31/2024 | N/A | -143 | -124 | -126 | 6 |
12/31/2023 | N/A | -125 | -123 | -101 | N/A |
9/30/2023 | N/A | -231 | -125 | -103 | N/A |
6/30/2023 | N/A | -236 | -127 | -103 | N/A |
3/31/2023 | N/A | -240 | -132 | -104 | N/A |
12/31/2022 | N/A | -243 | -120 | -103 | N/A |
9/30/2022 | N/A | -138 | -121 | -99 | N/A |
6/30/2022 | N/A | -149 | -125 | -99 | N/A |
3/31/2022 | N/A | -141 | -112 | -90 | N/A |
12/31/2021 | N/A | -123 | -98 | -80 | N/A |
9/30/2021 | N/A | -154 | -103 | -70 | N/A |
6/30/2021 | N/A | -119 | -81 | -54 | N/A |
3/31/2021 | N/A | -96 | -81 | -43 | N/A |
12/31/2020 | N/A | -102 | -71 | -33 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERAS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ERAS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ERAS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ERAS is forecast to have no revenue next year.
High Growth Revenue: ERAS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ERAS is forecast to be unprofitable in 3 years.